BACKGROUND: There are still limited data on the efficacy and safety of repeated donations of granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPCs) for allogeneic transplantation. STUDY DESIGN AND METHODS: Sixty-seven healthy donors undergoing two consecutive mobilizations of PBPCs within a median interval of 5 months (range, 0.1-47 months) were investigated. For both first mobilization (FM) and second mobilization (SM), G-CSF (lenograstim) at 7.5 microg per kg per day was administered. RESULTS: The nonhematologic side effects were comparable between both mobilizations. A significantly lower yield of CD34+ cells x 10(6) per kg of donor weight was obtained on Day 5 of SM in female (n = 31; FM, 5.0; SM, 3.23; p = 0.008) but not in male (n = 36; FM, 5.96; SM, 5.36; p = 0.24) donors. Multivariate analysis identified a lower CD34+ blood concentration on Day 5 of FM (p < 0.001) as well as female sex (p = 0.015) as independent risk factors for a lower yield of progenitor cells, whereas donor age and body mass index, interval between donations, and schedule of G-CSF application showed no significant impact. CONCLUSION: The identified risk factors allow the estimation of the efficacy of a SM in an individual donor before G-CSF administration, thus avoiding distress to both the donor and the recipient.
BACKGROUND: There are still limited data on the efficacy and safety of repeated donations of granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPCs) for allogeneic transplantation. STUDY DESIGN AND METHODS: Sixty-seven healthy donors undergoing two consecutive mobilizations of PBPCs within a median interval of 5 months (range, 0.1-47 months) were investigated. For both first mobilization (FM) and second mobilization (SM), G-CSF (lenograstim) at 7.5 microg per kg per day was administered. RESULTS: The nonhematologic side effects were comparable between both mobilizations. A significantly lower yield of CD34+ cells x 10(6) per kg of donor weight was obtained on Day 5 of SM in female (n = 31; FM, 5.0; SM, 3.23; p = 0.008) but not in male (n = 36; FM, 5.96; SM, 5.36; p = 0.24) donors. Multivariate analysis identified a lower CD34+ blood concentration on Day 5 of FM (p < 0.001) as well as female sex (p = 0.015) as independent risk factors for a lower yield of progenitor cells, whereas donor age and body mass index, interval between donations, and schedule of G-CSF application showed no significant impact. CONCLUSION: The identified risk factors allow the estimation of the efficacy of a SM in an individual donor before G-CSF administration, thus avoiding distress to both the donor and the recipient.
Authors: David F Stroncek; Bronwen E Shaw; Brent R Logan; Deidre M Kiefer; Bipin N Savani; Paolo Anderlini; Christopher N Bredeson; Peiman Hematti; Siddhartha Ganguly; Miguel Angel Diaz; Hisham Abdel-Azim; Ibrahim Ahmed; Dipnarine Maharaj; Matthew Seftel; Amer Beitinjaneh; Sachiko Seo; Jean A Yared; Joerg Halter; Paul V O'Donnell; Gregory A Hale; Zachariah DeFilipp; Hillard Lazarus; Jane L Liesveld; Zheng Zhou; Pashna Munshi; Richard F Olsson; Kimberly Anne Kasow; Jeffrey Szer; Galen E Switzer; Pintip Chitphakdithai; Nirali Shah; Dennis L Confer; Michael A Pulsipher Journal: Biol Blood Marrow Transplant Date: 2017-09-25 Impact factor: 5.742
Authors: Robert N Lown; Sameer Tulpule; Nigel H Russell; Charles F Craddock; Rochelle Roest; J Alejandro Madrigal; Bronwen E Shaw Journal: Haematologica Date: 2013-06-28 Impact factor: 9.941
Authors: Sandhya R Panch; Brent Logan; Jennifer A Sees; Stephanie Bo-Subait; Bipin Savani; Nirali N Shah; Jack W Hsu; Galen Switzer; Hillard M Lazarus; Paolo Anderlini; Peiman Hematti; Dennis Confer; Michael A Pulsipher; Bronwen E Shaw; David F Stroncek Journal: Transplant Cell Ther Date: 2021-03-09